Checkpoint Inhibition of KIR2D With the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients With Myeloma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1108
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

A Phase II Trial of Pan-Kir2d Blockade With IPH2101 in Smoldering Multiple Myeloma

Haematologica
Hematology
2014English

Immune Checkpoint Inhibition in Patients With Brain Metastases

Annals of Translational Medicine
Medicine
2016English

213Bi Radioimmunotherapy With an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2013English

Inhibition of Increased Circulating TFH Cell by Anti-Cd20 Monoclonal Antibody in Patients With Type 1 Diabetes

PLoS ONE
Multidisciplinary
2013English

Identification of Human Plasma Cells With a Lamprey Monoclonal Antibody

JCI insight
Medicine
2016English

Efficient Inhibition of P-Glycoprotein-Mediated Multidrug Resistance With a Monoclonal Antibody.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1992English

A Phase 1 Study of Lirilumab (Antibody Against Killer Immunoglobulin-Like Receptor Antibody KIR2D; IPH2102) in Patients With Solid Tumors and Hematologic Malignancies

Oncotarget
Oncology
2018English

Inhibition of QPCTL Induces Myeloid Immune Checkpoint Blockade

Cancer Discovery
Oncology
2019English

The Mechanism of Action of the Anti-Cd38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy